To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Study Number

1333721

Phase

III

Age Group

Adult

Principal Investigator

Eunice Wang

Purpose

The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.

Check your eligibility for this trial

Check now

Full Title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3K; Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis

ClinicalTrials.Gov ID

NCT04551066

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.